Cyrus Selects CYR212 for IgG-Driven Autoimmune Diseases Like MG
09 Jan 2025 //
BUSINESSWIRE
Cyrus Bio Demonstrates IdeS Redosability For Autoimmune Disease
11 Dec 2024 //
BUSINESSWIRE
Cyrus Biotech to Present Protein Engineering & IgG Protease Data
11 Nov 2024 //
BUSINESSWIRE
Cyrus Congratulates Nobel Laureate David Baker
10 Oct 2024 //
BUSINESSWIRE
Cyrus Spins Out Levitate Bio For Protein AI Services
11 Jun 2024 //
BUSINESSWIRE
Cyrus to Present Its Novel IgG-degrading IdeS Enzyme Development Candidates
16 Jan 2024 //
BUSINESSWIRE
Cyrus` ACE2.v2.4, strongly binds and neutralizes SARS-CoV-2 omicron variant
27 Dec 2021 //
BUSINESSWIRE
Seattle biotech closes $18M Series B — and acquires a company; Another George
06 Dec 2021 //
ENDPTS